Tolerance for Novogen

Interim results from a Phase II clinical trial in prostate cancer patients by Novogen’s subsidiary Marshall Edwards have shown the oral dose is well tolerated with no serious adverse events.

The US trial is studying the anti-tumour effects of phenoxodiol, an inhibitor of the pro-survival regulator sphingosine-1-phosphate (S-1-P).

Marshall Edwards is developing the product as a combination therapy for chemo-resistant ovarian cancer and as a monotherapy for cervical cancer.

The compound is also being studied as a monotherapy in prostate cancer, and in combination with the chemotherapy drugs cisplatin or carboplatin.

A study conducted by St George Hospital’s Professor Paul de Souza found phenoxodiol was able to enhance the activity of cisplatin and carboplatin in prostate cancer cells in vitro.

For the full story, see the March/April issue of Australian Life Scientist.